Valdecoxib
Specifications
181695-72-7CAS Number
448-010-8EC Number
4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamideIUPAC Name
C16H14N2O3SChemical Formula
314.4 g/molMolecular Weight
Valdecoxib; 181695-72-7; Bextra; 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide; Valdyn; SC-65872; SC 65872; 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide; valdecoxibum; DTXSID6044226; p-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; NSC-759846; 4-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide; 2919279Q3W; DTXCID4024226; CHEBI:63634; 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide; RefChem:56405; M01AH03; 448-010-8; Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-; Kudeq; MFCD00950568; 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzene-1-sulfonamide; YM-974; CHEMBL865; Valdecoxib-13C2, 15N; COX; NCGC00095129-01; Valdecoxib [USAN]; Valecoxib; SMR000466327; CAS-181695-72-7; Parecoxib Impurity 2; HSDB 7302; Valdecoxib (USAN/INN); Valdecoxib [USAN:INN:BAN]; UNII-2919279Q3W; 4-(5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonamide; ND-0214; Valdecoxib (Standard); Spectrum_001747; 2aw1; VALDECOXIB [MI]; VALDECOXIB [INN]; Spectrum2_000508; Spectrum3_001001; Spectrum4_001129; Spectrum5_001476; VALDECOXIB [HSDB]; VALDECOXIB [VANDF]; SCHEMBL3356; VALDECOXIB [MART.]; VALDECOXIB [WHO-DD]; BSPBio_002721; KBioGR_001617; KBioSS_002227; MLS000759433; MLS001165699; MLS001195631; MLS001424105; SPECTRUM1504302; VALDECOXIB [EMA EPAR]; SPBio_000435; 4-(Methyl-3-phenyl-isoxazol-4-yl)-benzenesulfonamide; cid_119607; GTPL2894; orb1225877; orb1310822; VALDECOXIB [ORANGE BOOK]; Valdecoxib, >=98% (HPLC); BDBM13063; KBio2_002227; KBio2_004795; KBio2_007363; KBio3_001941; EX-A241; MSK8007; GLXC-05758; HMS1922J21; HMS2051P07; HMS2232P23; HMS3372D12; HMS3393P07; HMS3652I04; HMS3715L18; HMS3885O20; HMS5082A04; Pharmakon1600-01504302; Tox21_111438; AC-120; CCG-39589; EBC-26753; HY-15762R; NSC759846; s4049; AKOS000280920; Tox21_111438_1; CS-1674; DB00580; FV28650; NC00184; NSC 759846; SB19519; MRF-0000216; NCGC00095129-02; NCGC00095129-03; NCGC00095129-06; NCGC00095129-07; Valdecoxib, analytical reference material; HY-15762; SY115891; DB-044435; UNM-0000305814; NS00009831; SW197564-2; V0245; C21552; D02709; AB00639996-08; AB00639996_10; EN300-7393031; F320060; Q347613; SR-01000759421; SR-01000759421-4; 4-[5-methyl-3-phenylisoxazol-4-yl]benzensulfonamide; BRD-K12994359-001-02-8; BRD-K12994359-001-14-3; BRD-K12994359-001-18-4; Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI); Benzenesulfonamide, 4-?(5-?methyl-?3-?phenyl-?4-?isoxazolyl)?-; InChI=1/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20Synonyms
